U
NVAX icon

UBS’s Novavax NVAX Stock Holding History

UBS’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$233K Buy
2,790
+70
+3% +$6.33K ﹤0.01% 5034
2014
Q2 		$251K Sell
2,720
-260
-9% -$22.9K ﹤0.01% 4916
2014
Q1 		$270K Buy
2,980
+960
+48% +$107K ﹤0.01% 4860
2013
Q4 		$207K Sell
2,020
-2,830
-58% -$200K ﹤0.01% 5266
2013
Q3 		$306K Buy
4,850
+4,130
+574% +$233K ﹤0.01% 4680
2013
Q2 		$30K Buy
+720
New +$31.2K ﹤0.01% 7383

Other funds holding NVAX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

UBS's NVAX Position: Q3 2014 in Review

UBS increased its Novavax (NVAX) stake by 81% in Q3 2014, buying an estimated $108K and bringing the position to 2,683 shares worth $224K. The position accounts for ﹤0.01% of the portfolio, ranked #5079.

UBS first reported a position in NVAX in Q2 2013 and has held it in 6 quarters since. The position peaked at $237K in Q4 2013. 143 funds tracked by Wall St. Rank hold NVAX as of Q3 2014.

  • UBS held 2,683 shares of Novavax worth $224K as of Q3 2014.
  • UBS bought 1,200 Novavax shares in Q3 2014, an estimated $108K.
  • Novavax made up ﹤0.01% of UBS's portfolio in Q3 2014, its #5079 holding.
  • UBS first reported a position in Novavax in Q2 2013 and has held it in 6 quarters since.
  • UBS's Novavax position peaked at $237K in Q4 2013.
  • 143 funds tracked by Wall St. Rank held Novavax as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.